Our data further show that small molecule-mediated suppression of TET1 can be a therapeutic option for MB subgroups having highly expressed TET1. These findings provide an insight into a new epigenetic driver, “epi-driver,” in pediatric brain tumor and the biological importance of the driver in tumor-associated signaling pathway. This evidence concerns the gene TET1 and neoplasm.